Why carry out this study?

Psoriasis is a chronic, immune-mediated inflammatory skin disease. Although not a life-threatening disease, the related physical and psychological burden means psoriasis has a major impact on the quality of life of patients.

There is only a limited amount of published real-world evidence (RWE) data for brodalumab.

What was learned from this study?

The therapy of psoriasis with brodalumab was effective and tolerable and resulted in significantly reduced psoriasis severity and symptoms in daily practice.

The primary endpoint of an absolute Psoriasis Area Severity Index (PASI) ≤ 3 after 12 weeks of treatment was achieved by 95.9% of patients. The static Physician’s Global Assessment (sPGA) success (defined as clear = 0 and almost clear = 1) at week 52 was achieved by 92.1% of patients.

Patients attested to a clear benefit from the therapy, including an improvement in their quality of life and a high level of satisfaction with the therapy.